Business Description
UBI Pharma Inc
ISIN : TW0006562002
Description
UBI Pharma Inc is a Taiwan-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing of novel protein drugs and specialty injectables. Its products include Olanzapine, Levetiracetam, Lamivudine, Nevirapine, Efavirenz, and Terbutaline.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | 4.77 | |||||
| Interest Coverage | 0.74 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.41 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 78 | |||||
| 3-Year FCF Growth Rate | 21.9 | |||||
| 3-Year Book Growth Rate | 27.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.69 | |||||
| 9-Day RSI | 20.49 | |||||
| 14-Day RSI | 19.72 | |||||
| 6-1 Month Momentum % | -2.67 | |||||
| 12-1 Month Momentum % | -28.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.11 | |||||
| Quick Ratio | 2.67 | |||||
| Cash Ratio | 1.72 | |||||
| Days Inventory | 77.34 | |||||
| Days Sales Outstanding | 58.67 | |||||
| Days Payable | 23.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.1 | |||||
| Shareholder Yield % | 3.43 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 30.39 | |||||
| Operating Margin % | 1.24 | |||||
| Net Margin % | 0.12 | |||||
| FCF Margin % | -17.63 | |||||
| ROE % | 0.07 | |||||
| ROA % | 0.04 | |||||
| ROIC % | 0.19 | |||||
| ROC (Joel Greenblatt) % | 1.45 | |||||
| ROCE % | 0.86 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1395 | |||||
| PE Ratio without NRI | 498.22 | |||||
| PS Ratio | 2.5 | |||||
| PB Ratio | 1.41 | |||||
| Price-to-Tangible-Book | 1.79 | |||||
| Price-to-Operating-Cash-Flow | 225 | |||||
| EV-to-EBIT | 131.85 | |||||
| EV-to-EBITDA | 16.91 | |||||
| EV-to-Revenue | 2.73 | |||||
| EV-to-FCF | -17.87 | |||||
| Price-to-Graham-Number | 6.28 | |||||
| Price-to-Net-Current-Asset-Value | 126.82 | |||||
| Earnings Yield (Greenblatt) % | 0.76 | |||||
| FCF Yield % | -6.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UBI Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 648.625 | ||
| EPS (TTM) (NT$) | 0.01 | ||
| Beta | 11.33 | ||
| Volatility % | 19.98 | ||
| 14-Day RSI | 19.72 | ||
| 14-Day ATR (NT$) | 2.021585 | ||
| 20-Day SMA (NT$) | 24.0425 | ||
| 12-1 Month Momentum % | -28.1 | ||
| 52-Week Range (NT$) | 10 - 42.538232 | ||
| Shares Outstanding (Mil) | 118.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UBI Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
UBI Pharma Inc Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
UBI Pharma Inc Frequently Asked Questions
What is UBI Pharma Inc(ROCO:6562)'s stock price today?
The current price of ROCO:6562 is NT$13.95. The 52 week high of ROCO:6562 is NT$42.54 and 52 week low is NT$10.00.
When is next earnings date of UBI Pharma Inc(ROCO:6562)?
The next earnings date of UBI Pharma Inc(ROCO:6562) is .
Does UBI Pharma Inc(ROCO:6562) pay dividends? If so, how much?
UBI Pharma Inc(ROCO:6562) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers